Literature DB >> 29152729

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Ursula Amstutz1, Linda M Henricks2, Steven M Offer3, Julia Barbarino4, Jan H M Schellens2,5, Jesse J Swen6, Teri E Klein4, Howard L McLeod7, Kelly E Caudle8, Robert B Diasio3,9, Matthias Schwab10,11,12.   

Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29152729      PMCID： PMC5760397          DOI： 10.1002/cpt.911

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  40 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Authors:  Maarten J Deenen; Jolien Tol; Artur M Burylo; Valerie D Doodeman; Anthonius de Boer; Andrew Vincent; Henk-Jan Guchelaar; Paul H M Smits; Jos H Beijnen; Cornelis J A Punt; Jan H M Schellens; Annemieke Cats
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 3.  Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

Authors:  Didier Meulendijks; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Cancer Treat Rev       Date:  2016-08-13       Impact factor: 12.111

4.  Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Authors:  Ursula Amstutz; Steven M Offer; Johanna Sistonen; Markus Joerger; Robert B Diasio; Carlo R Largiadèr
Journal:  Clin Cancer Res       Date:  2015-02-05       Impact factor: 12.531

5.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Authors:  Erick Gamelin; Remy Delva; Jacques Jacob; Yacine Merrouche; Jean Luc Raoul; Denis Pezet; Etienne Dorval; Gilles Piot; Alain Morel; Michele Boisdron-Celle
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

6.  Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Authors:  Didier Meulendijks; Linda M Henricks; André B P van Kuilenburg; Bart A W Jacobs; Abidin Aliev; Lisette Rozeman; Judith Meijer; Jos H Beijnen; Hiltje de Graaf; Annemieke Cats; Jan H M Schellens
Journal:  Cancer Chemother Pharmacol       Date:  2016-08-20       Impact factor: 3.333

7.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Authors:  Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio
Journal:  Cancer Res       Date:  2014-03-19       Impact factor: 12.701

Review 8.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 9.  Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Authors:  Dan Rosmarin; Claire Palles; David Church; Enric Domingo; Angela Jones; Elaine Johnstone; Haitao Wang; Sharon Love; Patrick Julier; Claire Scudder; George Nicholson; Anna Gonzalez-Neira; Miguel Martin; Daniel Sargent; Erin Green; Howard McLeod; Ulrich M Zanger; Matthias Schwab; Michael Braun; Matthew Seymour; Lindsay Thompson; Benjamin Lacas; Valérie Boige; Nuria Ribelles; Shoaib Afzal; Henrik Enghusen; Søren Astrup Jensen; Marie-Christine Etienne-Grimaldi; Gérard Milano; Mia Wadelius; Bengt Glimelius; Hans Garmo; Milena Gusella; Thierry Lecomte; Pierre Laurent-Puig; Eva Martinez-Balibrea; Rohini Sharma; Jesus Garcia-Foncillas; Zdenek Kleibl; Alain Morel; Jean-Pierre Pignon; Rachel Midgley; David Kerr; Ian Tomlinson
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 50.717

10.  Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.

Authors:  Luo Fang; Wenxiu Xin; Haiying Ding; Yiwen Zhang; Like Zhong; Hong Luo; Jingjing Li; Yunshan Yang; Ping Huang
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379
View more
  115 in total

1.  Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.

Authors:  Marelize Swart; Wesley M Stansberry; Victoria M Pratt; Elizabeth B Medeiros; Patrick J Kiel; Fei Shen; Bryan P Schneider; Todd C Skaar
Journal:  J Mol Diagn       Date:  2019-02-20       Impact factor: 5.568

2.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

3.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

4.  Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing.

Authors:  Reynold C Ly; Remington E Schmidt; Patrick J Kiel; Victoria M Pratt; Bryan P Schneider; Milan Radovich; Steven M Offer; Robert B Diasio; Todd C Skaar
Journal:  JCO Precis Oncol       Date:  2020-06-12

5.  Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.

Authors:  Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Masae Sekido; Ryotaro Ohkuma; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Takuya Tsunoda; Toshikazu Ikusue; Kouji Kobayashi; Atsushi Hisamatsu; Hirokazu Toshima; Ken Shimada; Ken-Ichi Fujita
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-26       Impact factor: 3.333

6.  Dose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracil.

Authors:  Shikshya Shrestha; Erin E Tapper; Colbren Scout Trogstad-Isaacson; Timothy J Hobday; Steven M Offer; Robert B Diasio
Journal:  JCO Precis Oncol       Date:  2018-10-03

Review 7.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

8.  Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Authors:  Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
Journal:  Glob Health Med       Date:  2020-08-31

Review 9.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.